loading page

One-year Outcome after Transcatheter Aortic Valve Replacement for Aortic Regurgitation: A Single-Center Study
  • +5
  • Lulu Liu,
  • Xiaoling Yao,
  • Ying Peng,
  • Weina Huang,
  • Jun Shi,
  • Hong Qian,
  • Yilong Chen,
  • Yingqiang Guo
Lulu Liu
Sichuan University West China Hospital

Corresponding Author:474036265@qq.com

Author Profile
Xiaoling Yao
Sichuan University West China Hospital
Author Profile
Ying Peng
Sichuan University West China Hospital
Author Profile
Weina Huang
Sichuan University West China Hospital
Author Profile
Jun Shi
Sichuan University West China Hospital
Author Profile
Hong Qian
Sichuan University West China Hospital
Author Profile
Yilong Chen
Sichuan University West China Hospital
Author Profile
Yingqiang Guo
Sichuan University West China Hospital
Author Profile

Abstract

Background: Presently, there are limited reports in the literature on the post-operative (mid-term) clinical outcome for pure Aortic Regurgitation (AR) following Transcatheter Aortic Valve Replacement (TAVR). Methods: Between March 2014 and June 2019, a total of 134 high-risk patients with pure, symptomatic severe AR patients were enrolled in the current study. The outcome was assessed according to the VARC-2 criteria. Procedural results, clinical outcomes, and the patients’ hemodynamics for a period of 1-year were analyzed. Results: Patient mean was 73.1±6.4 years and 25.4% were female. The average STS score was 9.8+5.3%. Procedural success was 97.1% (130/134), and the device success rate was 96.3% (129/134). Five cases were converted to open surgery, while two patients underwent valvular reinterventions (surgical aortic valve replacement for thrombosis and increasing paravalvular regurgitation). The mean aortic valve gradient was 10.2±4.1 mmHg, while the moderate and severe aortic regurgitation was 1.6% at 1 year. Paravalvular regurgitation was none/trivial in 79.8% and mild in 18.5%. The 1-year all-cause mortality rate was 7.4%. At 1-year, the stroke incidence rate was 2.2%. And pacemaker was implanted in 8.9% of the enrolled patients. Conclusions: In high-risk patients undergoing transapical-TAVR for AR, the use of the J-Valve is safe and effective TAVR should be considered as a reasonable option for high-risk patients with pure AR.
08 Aug 2021Submitted to Journal of Cardiac Surgery
09 Aug 2021Submission Checks Completed
09 Aug 2021Assigned to Editor
28 Aug 2021Reviewer(s) Assigned
02 Nov 2021Editorial Decision: Revise Minor
12 Nov 20211st Revision Received
12 Nov 2021Submission Checks Completed
12 Nov 2021Assigned to Editor
12 Nov 2021Reviewer(s) Assigned
12 Nov 2021Review(s) Completed, Editorial Evaluation Pending
22 Dec 2021Editorial Decision: Accept
18 Jan 2022Published in Journal of Cardiac Surgery. 10.1111/jocs.16238